Skip to Main Content
Phase II

An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)

  • Study HIC#:2000029804
  • Last Updated:07/30/2023

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).

    Contact Us

    For more information about this study, including how to volunteer, contact:

    Jessica Goepfert

    Help Us Discover!

    You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact, or call +18779788343 for more information.

    Trial Purpose and Description

    Etavopivat is designed to activate PKR and thereby modulate RBC metabolism by impacting two critical pathways in RBCs. The etavopivat clinical development program will investigate whether decreasing 2,3-DPG may help oxygen bind to hemoglobin (i.e. increasing oxygen affinity), and thereby increase ATP and impact RBC function. This study is a randomized, placebo-controlled, double-blind, multicenter Phase 2/3 study of patients age 12 to 65 years (inclusive), with sickle cell disease. There are two planned interim analyses in this study design. Initially, patients will be randomized at 1:1:1 to one of two dose levels of etavopivat or placebo. At the first interim analysis, one of the two etavopivat dose levels will be selected for the Phase 3 portion of the study, in which patients will be randomized at 1:1 to the selected etavopivat dose or placebo. Efficacy on hemoglobin will be evaluated at the second interim analysis, and then will be tested along with evaluation of efficacy on vaso-occlusive crises at the final analysis. Following completion of 52 weeks of double-blind treatment, patients may enter a 52-week etavopivat open-label extension period.

    Eligibility Criteria

    Key Inclusion Criteria:

    • Provision of consent
    • Patient has a confirmed diagnosis of sickle cell disease
    • At least 2 episodes of vaso-occlusive crises in the past 12 months
    • Hemoglobin ≥ 5.5 and ≤ 10.5 g/dL (≥ 55 and ≤ 105 g/L) during screening
    • Patients taking hydroxyurea, must demonstrate a stable dose for at least 90 days prior to start of study treatment
    • Patients on crizanlizumab or L-glutamine treatment at the time of consent must be on a stable dose for ≥ 12 months and must be ≥ 80% compliant with the planned regimen at the time of consent and meet the VOC eligibility criteria
    • Female patients of childbearing potential must use highly effective methods of contraception, male patients are willing to use barrier methods of contraception

    Key Exclusion Criteria:

    • More than 10 vaso-occlusive crises within the past 12 months
    • Female who is breastfeeding or pregnant
    • Hepatic dysfunction characterized by:

      • Alanine aminotransferase (ALT) > 4.0 × upper limit of normal (ULN)
      • Direct bilirubin > 3.0 × ULN
    • Known HIV positivity
    • Active hepatitis B or hepatitis C infection
    • Severe renal dysfunction or on chronic dialysis
    • History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to consent including but not limited to the following:

      • Unstable angina pectoris or myocardial infarction or elective coronary intervention
      • Congestive heart failure requiring hospitalization
      • Uncontrolled clinically significant arrhythmias
      • Symptomatic pulmonary hypertension
    • History of overt clinical stroke within previous 2 years or any history of an intracranial hemorrhage
    • History of deep venous thrombosis requiring systemic anti-coagulation therapy for ≥ 6 weeks, occurring within 6 months prior to Day 1 of study treatment.

    Prior/Concomitant Therapy

    • Patients receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion)
    • Receiving or use of concomitant medications that are strong inducers of CYP3A4/5 within 2 weeks of starting study treatment or anticipated need for such agents during the study
    • Use of voxelotor within 28 days prior to starting study treatment or anticipated need for this agent during the study
    • Use of an experimental selectin antagonist (eg, monoclonal antibody or small molecule) within 28 days of starting study treatment or anticipated need for such agents during the study
    • Use of erythropoietin or other hematopoietic growth factor treatment within 28 days of starting study treatment or anticipated need for such agents during the study
    • Receipt of prior cellular-based therapy (eg, hematopoietic cell transplant, gene modification therapy)